

UNITED STATES PATENT AND TRADEMARK OFFICE  
**CERTIFICATE OF CORRECTION**

PATENT NO. : 7,611,700 B2  
APPLICATION NO. : 10/658834  
DATED : November 3, 2009  
INVENTOR(S) : Gantier et al.

Page 1 of 2

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

At column 7, lines 15-16, please replace “SEQ ID Nos: 233-289), 989-1015, and 1016-1302)compared” with -- SEQ ID Nos: 233-289, 989-1015, and 1016-1302) compared --;

At column 7, line 47, please replace “(SEQ ID NO:216)based” with -- (SEQ ID NO:216) based --;

At column 7, lines 51-52, please replace “SEQ ID Nos: 794-849), compared” with -- SEQ ID Nos: 794-849) compared --;

At column 7, lines 57-58, please replace “SEQ ID Nos: 896-939), compared” with -- SEQ ID Nos: 896-939) compared --;

At column 7, line 64, please replace “(SEQ ID NO:211),based” with -- (SEQ ID NO:211), based --;

At column 8, line 2, please replace “SEQ ID Nos: 729-760), compared” with -- SEQ ID Nos: 729-760) compared --;

At column 8, lines 8-9, please replace “SEQ ID Nos: 761-763), compared” with -- SEQ ID Nos: 761-763) compared --;

At column 8, lines 16-17, please replace “Nos: 940-977), compared to the wild-type sequence (SEQ ID NO: 201),based” with -- Nos: 940-977) compared to the wild-type sequence (SEQ ID NO: 201), based --;

At column 8, lines 21-22, please replace “SEQ ID Nos: 401-428), compared to residues 1-1000” with --SEQ ID Nos: 401-428) compared to residues 1-100 --;

At column 8, lines 29-30, please replace “SEQ ID Nos: 362-400), compared to the wild-type sequence (SEQ ID NO: 202),based” with -- SEQ ID Nos: 362-400) compared to the wild-type sequence (SEQ ID NO: 202), based --;

At column 8, lines 35-36, please replace “SEQ ID Nos: 603-630), compared” with -- SEQ ID Nos: 603-630) compared --;


At column 8, lines 40-41, please replace “SEQ ID Nos: 429-476), compared” with -- SEQ ID Nos: 429-476) compared --;

At column 8, lines 46-47, please replace “SEQ ID Nos:477-498), compared” with -- SEQ ID Nos: 477-498) compared --;

At column 8, lines 52-53, please replace “SEQ ID Nos: 543-567), compared” with -- SEQ ID Nos: 543-567) compared --;

Signed and Sealed this

Fourth Day of May, 2010



David J. Kappos  
*Director of the United States Patent and Trademark Office*

At column 8, lines 58-59, please replace “SEQ ID Nos: 568-602), compared” with -- SEQ ID Nos: 568-602) compared --;

At column 8, lines 64-65, please replace “SEQ ID Nos: 499-542), compared” with -- SEQ ID Nos: 499-542) compared --;

At column 47, line 50, please replace “IFN $\alpha$ cytokines” with -- IFN $\alpha$  cytokines --;

At column 47, line 57, please replace “herein The” with -- herein. The --;

At column 52, line 41, please replace “10/658,355,filed” with -- 10/658,355, filed --;

At column 66, line 50, please replace “prostatate” with -- prostate --;

At column 74, line 29, please replace “aliquots” with -- aliquots --;

At column 74, line 33, please replace “analysis.Residual” with -- analysis. Residual --;

At column 74, line 26, please replace “IFN  $\alpha$ ” with -- IFN- $\alpha$  --.

Column 87, line 32 to Column 87, line 47 should read

1. An isolated interferon (IFN) alpha cytokine, comprising an amino acid replacement in its sequence of amino acids, wherein:

an amino acid replacement is E41Q, whereby the interferon alpha cytokine exhibits increased resistance to proteolysis so that it can be administered orally compared to the unmodified interferon alpha cytokine that does not comprise the amino acid replacement; and

in the interferon-alpha cytokine the interferon is not glycosylated at E41Q; and

the unmodified interferon alpha cytokine is selected from among an interferon  $\alpha$ -2b (IFN $\alpha$ -2b), an interferon  $\alpha$ -2a (IFN $\alpha$ -2a), an interferon  $\alpha$ -2c (IFN $\alpha$ -2c) and consensus interferon whose sequences are set forth in SEQ ID Nos. 1, 182, 185 and 232, respectively.

Column 87, line 48 to Column 87, line 64 should read

2. An interferon alpha cytokine selected from among IFN $\alpha$ -2b, IFN $\alpha$ -2a, IFN $\alpha$ -2c, consensus interferon, IFN $\alpha$ -c, IFN $\alpha$ -d, IFN $\alpha$ -5, IFN $\alpha$ -6, IFN $\alpha$ -4, IFN $\alpha$ -4b, IFN $\alpha$ -I, IFN $\alpha$ -J, IFN $\alpha$ -H, IFN $\alpha$ -F and IFN $\alpha$ -8, each comprising the modification E41Q, wherein:

the sequence of a human wild-type interferon alpha for each of IFN $\alpha$ -2b, IFN $\alpha$ -2a, IFN $\alpha$ -2c, consensus interferon, IFN $\alpha$ -c, IFN $\alpha$ -d, IFN $\alpha$ -5, IFN $\alpha$ -6, IFN $\alpha$ -4, IFN $\alpha$ -4b, IFN $\alpha$ -I, IFN $\alpha$ -J, IFN $\alpha$ -H, IFN $\alpha$ -F and IFN $\alpha$ -8; is set forth in SEQ ID Nos. 1, 182, 185, 232, 183 and 186-195, respectively; the modification at E41Q increases resistance of the interferon alpha cytokine so that it can be administered orally;

the interferon alpha cytokine is not glycosylated at E41Q; and

residue 1 in each SEQ ID corresponds to residue 1 of the mature interferon-alpha.